There are currently 235 clinical trials in Spokane, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including Cancer Care Northwest - Spokane South, Providence Sacred Heart Medical Center and Children's Hospital, Evergreen Hematology and Oncology, PS and Premier Clinical Research. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed. Telisotuzum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Medical Oncology Associates /ID# 247003, Spokane, Washington
Conditions: Non Small Cell Lung Cancer
Register for Updates
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
NCT06018428
Recruiting
Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation. Part B is a multicenter, open-label study to assess the efficacy, safety, and tolerability of bempikibart (ADX-914) in participants with severe Alopecia Areata.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/12/2025
Locations: Spokane, Washington, Spokane, Washington
Conditions: Alopecia Areata
Register for Updates
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
NCT07108660
Recruiting
Prospective, multi-center, cluster-randomized trial of a hospital Infection Preventionist (IP)-led quality improvement study to provide clinical teams with just-in-time clinical education and reinforcement of existing best practices recommendations based on the output of a possible Central Line Associated Blood Stream Infection (CLABSI) Machine Learning (ML) prediction model. The objective is to determine whether providing this model to Infection Preventionists will decrease the CLABSI rates ve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Providence Sacred Heart Medical Center, Spokane, Washington
Conditions: Central Line Associated Blood Stream Infections (CLABSI)
Register for Updates
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #2041, Spokane, Washington
Conditions: Weight Loss
Register for Updates
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945
Recruiting
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body. Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose. This study is s... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/11/2025
Locations: Dermatology Specialists of Spokane, Spokane, Washington +1 locations
Conditions: Alopecia Areata
Register for Updates
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636
Recruiting
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies ha... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
08/11/2025
Locations: Spokane Eye Clinic /ID# 256338, Spokane, Washington
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Register for Updates
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
NCT05946941
Recruiting
The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Arthritis Northwest, Spokane, Washington
Conditions: Sjögren's Syndrome
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
NCT06850922
Recruiting
This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections). Phase II will investigate the safety, tolerability, pharmacokinetics (PK)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Spokane Eye Clinical Research, Spokane, Washington
Conditions: Diabetic Macular Edema
Register for Updates
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023
Recruiting
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Premier Clinical Research, Spokane, Washington
Conditions: Chronic Spontaneous Urticaria
Register for Updates
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134
Recruiting
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Inland Northwest Research, Spokane, Washington
Conditions: Parkinson's Disease
Register for Updates
Patient Retrospective Outcomes (PRO)
NCT01550575
Recruiting
This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Northwest Pain Care, Spokane, Washington
Conditions: Chronic Pain
Register for Updates
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
NCT05636176
Recruiting
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to u... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: Providence Med Research Ctr, Spokane, Washington
Conditions: Heart Failure
Register for Updates